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ABSTRACT 
 
There is a great need for biomarkers to diagnose neurodegenerative disorders, such as 
the cognitive disorders Alzheimer’s disease (AD) and frontotemporal dementia (FTD). 
Cerebrospinal fluid (CSF) is in contact with the extracellular fluid of the brain and is 
consequently a valuable medium for identifying biomarkers for neurological disorders. 
Biomarkers can be used for early identification of disease, to facilitate homogenous 
classification, and to extend our basic knowledge of disease pathogenesis. Proteomics, 
an approach for biomarker discovery, generally combines various separation 
techniques with mass spectrometry (MS) and bioinformatics to identify and 
characterize proteins, reflecting a defined state at a specific time point. The aim of this 
thesis was to develop and evaluate proteomic strategies for analysis of CSF proteins to 
reveal disease mechanisms and identify potential biomarkers to distinguish AD from 
FTD.  
Two approaches to improve the detection of CSF proteins by two-dimensional 
gel electrophoresis (2-DGE) were used. First, to enrich the proteins, CSF was 
prefractionated using liquid phase isoelectric focusing followed by 2-DGE profiling. 
Secondly, zoom 2D gels increased protein separation directly in the gels. These studies 
showed that in the CSF proteome of AD and FTD patients several proteins were 
differentially expressed, suggesting that different mechanisms are involved in the 
pathogenesis of these disorders.  
To validate some of the findings from the 2-DGE studies, β-trace, transthyretin 
(TTR), α-1-antitrypsin and cystatin C (CysC) were quantified in CSF. The 
concentrations of all these proteins, previously shown to bind amyloid-beta (Aβ) 
peptides, were reduced in AD CSF, while only CysC and β-trace were reduced in 
FTD. Furthermore, we found a strong positive correlation between β-trace, TTR and 
CysC, and levels of Aβ peptides specifically in the AD group, suggesting that a lack of 
proteins binding to Aβ peptides in AD CSF might cause increased extracellular Aβ 
aggregation, a major pathological hallmark in the AD brain. 
Additionally, we showed that incorrect storage conditions can influence the 
isoform levels of some CSF proteins. Thus, standardization of CSF sample handling is 
important in avoiding ambiguous results. Furthermore, very low-abundant neuron 
specific tau protein isoforms, were for the first time characterized in CSF using a 
targeted immunoprecipitation-MS approach, opening up new possibilities for further 
differentiation of tauopathies, including AD and FTD. 
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